UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Terminated
Unique ID issued by UMIN UMIN000005218
Receipt No. R000006192
Scientific Title A phase I/II study of combination therapy with S-1/ CPT-11 plus Panitumumab as second line therapy in metastatic colorectal cancer patients with KRAS wild type
Date of disclosure of the study information 2011/03/09
Last modified on 2019/05/23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A phase I/II study of combination therapy with S-1/ CPT-11 plus Panitumumab as second line therapy in metastatic colorectal cancer patients with KRAS wild type
Acronym A phase I/II study of combination therapy with S-1/ CPT-11 plus Panitumumab as second line therapy in metastatic colorectal cancer patients with KRAS wild type
(FUTURE1101)
Scientific Title A phase I/II study of combination therapy with S-1/ CPT-11 plus Panitumumab as second line therapy in metastatic colorectal cancer patients with KRAS wild type
Scientific Title:Acronym A phase I/II study of combination therapy with S-1/ CPT-11 plus Panitumumab as second line therapy in metastatic colorectal cancer patients with KRAS wild type
(FUTURE1101)
Region
Japan

Condition
Condition metastatic colorectal cancer
Classification by specialty
Gastrointestinal surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To evaluate efficacy and safety of combination therapy with S-1 and Irinotecan and Panitumumab,in patients with KRAS wild type colorectal cancer.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes phase1
recommend dose of 1st cycle

phase2
response rate
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Panitumumab;tri-weekly administration 9mg/kg. and CPT-11 is administered as an intravenous infusion at a dose of 150mg/m2(or 125 mg/m2)on day 1 and TS-1 is orally administered on days 1-14 of a 21-day cycle. Administration dose of TS-1 is based BSA : BSA<1.25m2, 40mg twice daily; 1.25-1.5m2, 50mg twice daily; >1.5m2, 60mg twice daily.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >=
Gender Male and Female
Key inclusion criteria 1)Histologically confirmed colorectal cancer
2)Histologically confirmed KRAS wild type on the tumor tissue
3)Unresectable advanced or metastatic colorectal cancer
4) patients with tumor resistant/intolerant to oxaliplatin,fluoropyrimidine
5) ECOG performance status 0,1
6) Age between 20 to 80 years
7) Written informed consent
8) with a good condition of important organs
1.Hb >=9.0g/dl
2.WBC>= 3,000/mm3, <=12,000 mm3
3.neutrophil >= 1,500/mm3
4.platelet >= 100,000/mm3
5.Creatinine < 1.5mg/dl
6.Creatinine clealance: >=50mL/min
7.ALT/AST <= 100IU/l
(200 IU/l if the patients has liver metastasis)
8.total bilirubin <= 1.5mg/dl
9)Oral administration of S-1 is possible.
10)Life expectancy of more than 3 months.
11)Presence of measurable lesion
12)Periods from prior treatment have elapsed more than two weeks
13)Prior radiotherapy is not acceptable
Key exclusion criteria 1)Patients with severe complications,(severe cardiovascular disease,severe heart disease,heart failure,liver failure,renal failure or uncontrollable diabetes mellitus)
2)Patients with active infection
3)Patients with severe interstitial pneumonitis or pulmonary fibrosis
4)Patients with active double cancer
5)Patients with paralytic ileus, bowel obstruction
6)Patients with uncontrollable ascites and pleural effusion
7)Patients with diarrhea
8)Patients with the past history of severe allergic reactions
9)Patient with regular use of furucytocin or fenytoin,warfarin
10)psychiatric patients
11)pregnant or nursing patient or with intent to bear baby
12)Patients with the past history of treatment of S-1 and CPT-11 and Panitumumab, Cetuximab
13)Patients with regular use of steroids(oral or intravenous)
14)Patients with brain metastasis
15)Exclude the patients who are recognized as inadequate patients by doctors with responsibility in this trial
Target sample size 35

Research contact person
Name of lead principal investigator
1st name Yoichiro
Middle name
Last name Yoshida
Organization Fukuoka University School of medicine
Division name Department of Gastroenterologial Surgery
Zip code 814-0180
Address 7-45-1 Nanakuma, Jonan-ku, Fukuoka
TEL 0928011011
Email yy4160@yahoo.co.jp

Public contact
Name of contact person
1st name Yoichiro
Middle name
Last name Yoshida
Organization Fukuoka University School of medicine
Division name Department of Gastroenterologial Surgery
Zip code 814-0180
Address 7-45-1 Nanakuma, Jonan-ku,Fukuoka
TEL 0928011011
Homepage URL
Email yy4160@yahoo.co.jp

Sponsor
Institute Fukuoka Tumor Research(FUTURE)
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Fukuoka Univesity
Address 7-45-1, Nanakuma
Tel 0928011011
Email yy4160@yahoo.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2011 Year 03 Month 09 Day

Related information
URL releasing protocol No
Publication of results Unpublished

Result
URL related to results and publications No
Number of participants that the trial has enrolled 0
Results
No
Results date posted
2019 Year 05 Month 23 Day
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
No
Participant flow
No
Adverse events
No
Outcome measures
No
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2011 Year 02 Month 17 Day
Date of IRB
2011 Year 02 Month 17 Day
Anticipated trial start date
2011 Year 03 Month 01 Day
Last follow-up date
2012 Year 12 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2011 Year 03 Month 08 Day
Last modified on
2019 Year 05 Month 23 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006192

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.